SCYNEXIS has begun dosing in a Phase 1 single- and multiple-ascending dose study of its intravenous SCY-247, with initial results expected in 2026. The IV start follows September 2025 SAD/MAD data for the oral formulation showing favorable pharmacokinetics and pharmacodynamics and achieving target exposures for invasive fungal disease at doses lower than first-generation fungerps. The program holds QIDP and Fast Track designations.
The core development move is the shift to an IV route for SCY-247, a second-generation triterpenoid antifungal positioned for invasive candidiasis treatment and as prophylaxis against invasive fungal disease. For a pathogen set dominated by hospitalized, high-acuity patients, an IV option is table stakes if the asset is to challenge echinocandins and enable true step-up/step-down regimens that start inpatient and continue orally. SCYNEXIS’ earlier fungerp, ibrexafungerp, is licensed to GSK and is approved in VVC; SCY-247 represents the company’s effort to extend the class into systemic, hospital-relevant indications.
Strategically, this is an expansion play aimed at the inpatient infectious disease market where standard of care is IV-first and resistance patterns are worsening. The IV readout will determine whether SCY-247 can credibly support a seamless inpatient-to-outpatient pathway and differentiate on exposure, tolerability, and spectrum, particularly where azole and echinocandin resistance is rising and Candida auris remains a pressure point for stewardship teams. The QIDP/Fast Track package helps on timelines and market protections, but the more telling signal is the company’s emphasis on non-dilutive funding, suggesting a push to align the program with public health and biodefense priorities to underwrite costly hospital-based efficacy trials.
For sites and CROs, the IV program points to a development path that will rely on large academic centers and community hospitals with strong infectious disease infrastructure, rapid mycology diagnostics, and capacity for intensive PK sampling. If SCY-247 advances into treatment trials for invasive candidiasis, expect non-inferiority designs against echinocandins with all-cause mortality and clinical response endpoints at day 30, necessitating tight operational control of time-to-therapy, source control documentation, and susceptibility testing via central labs. Prophylaxis development would shift the footprint to transplant and hematologic oncology networks, where event-driven designs, background antifungal use, and drug–drug interaction management complicate execution. Regulators’ increasing focus on resistance, pathogen identification, and subgroup analyses by species and susceptibility will raise the bar on data completeness and real-time microbiology operations.
The near-term readouts that matter are basic but decisive: IV tolerability, infusion-related reactions, hepatic laboratory signals, and whether exposures match or extend the oral program to support high-risk populations without additive toxicity. If those boxes are checked, the next strategic choice is pivotal design. A head-to-head non-inferiority study versus an echinocandin in invasive candidiasis with a prespecified step-down to oral SCY-247 would test the full value proposition and could ease adoption in stewardship pathways. Prophylaxis will require careful comparator selection and DDI management in transplant/oncology settings, where posaconazole and fluconazole are entrenched. Manufacturing readiness for sterile injectables, sourcing of resistant isolates for surveillance and potential enrichment, and clarity on external funding or partnership will be gating issues through 2026. Watch for signals on spectrum against resistant Candida, the IV-to-oral bridge strategy, and whether SCYNEXIS secures government or strategic backing to carry the asset into hospital-scale studies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
